Christina Rubenhag appointed acting CEO and Peter Ehrenheim will assume the role as working Chairman of the Board of Boule Diagnostics

The Board of Directors of Boule Diagnostics AB has appointed Christina Rubenhag acting CEO and Group President as of January 19, 2020, the date on which Fredrik Dalborg leaves the position as CEO and Group President. Christina will maintain the position as acting CEO until the date on which Jesper Söderqvist assumes the position of CEO and Group President, on May 11, 2020 at the latest. During this period, the Chairman of the Board, Peter Ehrenheim, will change his role to working Chairman of the Board to support the Management team. The role as working Chairman of the Board will correspond to approximately two workdays per week. 

Christina Rubenhag has been the CFO of Boule Diagnostics since 2017 and arrived most recently from Biolin Scientific AB where she was employed for over five years, first as CFO and later as CEO. Christina was born in 1970, has a degree in business from Umeå University and has a broad experience in the fields of finance and economics as well as from different management positions.

For further information, please contact:
Peter Ehrenheim, Chairman of the Board, Boule Diagnostics AB, phone. + 46 706-67 57 11

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011.

The information was submitted for publication, through the agency of the contact person set out above at 16:15 CET on December 13, 2019.


  • Subscribe to our news